Form 424B3 - Prospectus [Rule 424(b)(3)]
19 Janvier 2024 - 12:02PM
Edgar (US Regulatory)
Filed pursuant to
Rule 424(b)(3)
Registration No. 333-264083
SUPPLEMENT NO 1. DATED January 19,
2024
TO PROSPECTUS SUPPLEMENT DATED June
16, 2023
(To Prospectus Dated May 5, 2022)
Edgewise Therapeutics,
Inc.
This Supplement
No. 1 to Prospectus Supplement (this “Supplement”) supplements and amends the Prospectus Supplement dated June 16, 2023 (the
“Prospectus Supplement”). This Supplement should be read in conjunction with the Prospectus Supplement and the accompanying
Prospectus dated May 5, 2022 (the “Prospectus”). This Supplement is qualified by reference to the Prospectus Supplement,
except to the extent that the information presented herein supersedes the information contained in the Prospectus Supplement.
On June 16, 2023,
we entered into a Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc. (“BofA”) relating to shares
of our common stock offered by the Prospectus Supplement and the accompanying Prospectus. In accordance with the terms of the Sales Agreement,
we may offer and sell shares of our common stock having an aggregate offering price of up to $125,000,000 from time to time through BofA,
acting as our sales agent, pursuant to at-the-market transactions (the “ATM”). As of the date of this Supplement, we have
sold an aggregate of 7,560,068 shares of our common stock pursuant to the Sales Agreement for aggregate gross proceeds of approximately
$59.9 million.
The purpose of
this Supplement is to suspend the ATM and to terminate the continuous offering by us under the Prospectus Supplement, effective on January
19, 2024. We will not make any sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus supplement
is filed with the Securities and Exchange Commission; however, the Sales Agreement remains in full force and effect.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
The date of this
Supplement No. 1 to Prospectus Supplement is January 19, 2024.
Edgewise Therapeutics (NASDAQ:EWTX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024